110
Participants
Start Date
April 9, 2021
Primary Completion Date
February 24, 2022
Study Completion Date
February 24, 2022
Transition from Xyrem to Xywav
This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
Jazz Pharmaceuticals Clinical Site, Palo Alto
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY